Surveillance is the standard management in low-risk cN0 penile squamous cell carcinoma (peSCC) patients. However, no previous analysis focused on early and long-term outcomes of these patients. We report on main oncological outcomes of a large series of low-risk cN0 peSCC patients. Between 1980 and 2017 included, 93 evaluable consecutive low-risk (ie, pT1a G1 cN0M0) peSCC patients underwent primary tumor surgery and either observation (74) or dynamic sentinel node biopsy (DSNB) (19) following a clinical diagnosis of T1 in 66 (71%), T2 in 15 (16.1%) and Tx in 12 (12.9%) patients, respectively. The statistical significance of differences in medians and proportions was tested with the Kruskal-Wallis and chi-square tests. Kaplan-Meier plots illustrated 5-year inguinal relapse (IR)-free survival rates. Median age was 60 years (IQR: 50-69 years). Median follow-up was 92 months (IQR 54-133 months). Surveillance was more frequently adopted in clinical (c)T1 than in cT2 tumors (79.7% vs. 36.8%). None of 19 patients who had DSNB had nodal metastasis. Overall, 7 (7.5%) out of 93 pT1aG1cN0 peSCC patients had IR after a median interval of 9 months. Of note, 1 patient only relapsed after 12 months of surveillance. After stratification according to IR, relapses occurred more frequently in younger patients (59 vs. 64 years, < .001). The 5-year IR-free survival rates for the entire cohort was 92% (95% Confidence interval [CI] 87-98%). Observation is a safe and effective management for low-risk peSCC patients. Younger patients may be offered a mini-invasive staging as an alternative.

中文翻译：

---

低风险临床 N0 阴茎鳞状细胞癌的监测或动态前哨淋巴结活检：单机构真实世界数据

监测是低风险 cN0 阴茎鳞状细胞癌 (peSCC) 患者的标准管理。然而，之前没有针对这些患者的早期和长期结果进行分析。我们报告了一系列低风险 cN0 peSCC 患者的主要肿瘤学结果。 1980 年至 2017 年间，93 名可评估的连续低风险（即 pT1a G1 cN0M0）peSCC 患者接受了原发性肿瘤手术，并在 66 名临床诊断为 T1 后进行观察（74）或动态前哨淋巴结活检（DSNB）（19） (71%)、T2 和 Tx 分别为 15 例 (16.1%) 和 12 例 (12.9%)。中位数和比例差异的统计显着性通过 Kruskal-Wallis 和卡方检验进行检验。 Kaplan-Meier 图显示了 5 年腹股沟无复发 (IR) 生存率。中位年龄为 60 岁（IQR：50-69 岁）。中位随访时间为 92 个月（IQR 54-133 个月）。临床 (c)T1 肿瘤比 cT2 肿瘤更频繁地采用监测（79.7% vs. 36.8%）。 19 名接受 DSNB 的患者均未出现淋巴结转移。总体而言，93 名 pT1aG1cN0 peSCC 患者中有 7 名 (7.5%) 在中位间隔 9 个月后出现 IR。值得注意的是，1 名患者在监测 12 个月后才复发。根据 IR 分层后，年轻患者复发的频率更高（59 岁 vs. 64 岁，< .001）。整个队列的 5 年无 IR 生存率为 92%（95% 置信区间 [CI] 87-98%）。观察对于低危 peSCC 患者来说是一种安全有效的治疗方法。年轻患者可能会接受微创分期作为替代方案。